Apollomics APLM
NASDAQ APLM
$23.86 -1.02 (-4.04%)
As of: Sep 10, 2026 · 11:04 AM EDT

Apollomics (APLM) Short term Debt (2023 - 2024)

Apollomics' (APLM) quarterly Short term Debt came in at $3.5 million in Q2 2024, down 17.19% quarter-over-quarter from $4.2 million in Q4 2023.

Analysis

Apollomics (APLM) Short term Debt (2023 - 2024) Analysis & Trends

Apollomics (APLM) has reported Short term Debt for 2 consecutive years, with $3.5 million the latest figure, recorded in Q2 2024.

  • On a quarterly basis, Short term Debt changed N/A year-over-year to $3.5 million in Q2 2024; TTM through Jun 2024 was $3.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $4.2 million, changed N/A from the prior year.
  • Short term Debt was $3.5 million for Q2 2024 at Apollomics, down from $4.2 million in the prior quarter.
  • Over five years, Short term Debt peaked at $4.2 million in Q4 2023 and troughed at $3.5 million in Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Apollomics 34.50 Mn 31.23 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 3.51 Mn
Dec 31, 2023 4.24 Mn